Department of Conservative Dentistry, Laboratory of Periodontal Biology, Faculty of Dentistry, University of Chile, Santiago, Chile.
Department of Medicine and Oral Pathology, Laboratory of Microbiology, Faculty of Dentistry, University of Chile.
J Periodontol. 2016 Aug;87(8):944-52. doi: 10.1902/jop.2016.150665. Epub 2016 Mar 4.
Probiotics are living microorganisms that provide beneficial effects for the host when administered in proper quantities. The aim of this double-masked placebo-controlled parallel-arm randomized clinical trial is to evaluate the clinical effects of a Lactobacillus rhamnosus SP1-containing probiotic sachet as an adjunct to non-surgical therapy.
Twenty-eight systemically healthy volunteers with chronic periodontitis were recruited and monitored clinically at baseline and 3, 6, 9, and 12 months after therapy. Clinical parameters measured included plaque accumulation, bleeding on probing, probing depths (PDs), and clinical attachment loss. Patients received non-surgical therapy, including scaling and root planing (SRP), and were assigned randomly to a test (SRP + probiotic, n = 14) or control (SRP + placebo, n = 14) group. The intake, once a day for 3 months, of an L. rhamnosus SP1 probiotic sachet commenced after the last session of SRP.
Both test and control groups showed improvements in clinical parameters at all time points evaluated. However, the test group showed greater reductions in PD than the control. Also, at initial visits and after 1-year follow-up, the test group showed a statistically significant reduction in the number of participants with PD ≥6 mm, indicating a reduced need for surgery, in contrast to the placebo group.
The results of this trial indicate that oral administration of L. rhamnosus SP1 resulted in similar clinical improvements compared with SRP alone.
益生菌是指当以适当数量给予宿主时,能为宿主提供有益影响的活微生物。本双盲安慰剂对照平行臂随机临床试验的目的是评估含有鼠李糖乳杆菌 SP1 的益生菌包作为非手术治疗辅助剂的临床效果。
招募了 28 名系统性健康的慢性牙周炎志愿者,并在治疗前、治疗后 3、6、9 和 12 个月进行临床监测。测量的临床参数包括菌斑积聚、探诊出血、探诊深度(PD)和临床附着丧失。患者接受非手术治疗,包括洁治和根面平整(SRP),并随机分配到试验(SRP+益生菌,n=14)或对照(SRP+安慰剂,n=14)组。在 SRP 最后一次治疗后,每天摄入一次 L. rhamnosus SP1 益生菌包,持续 3 个月。
试验组和对照组在所有评估时间点的临床参数均有所改善。然而,试验组 PD 的减少幅度大于对照组。此外,在初始就诊和 1 年随访后,试验组 PD≥6mm 的参与者数量显著减少,表明与安慰剂组相比,手术需求减少,这表明该益生菌具有减少手术需求的潜力。
该试验的结果表明,与单独接受 SRP 相比,口服给予鼠李糖乳杆菌 SP1 可获得相似的临床改善效果。